Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 74, n° 1
page 171 (janvier 2016)
Doi : 10.1016/j.jaad.2015.08.051
Research Letters

Botulinum toxin for depression: Does patient appearance matter?
 

Jason S. Reichenberg, MD a, b, , Aaron J. Hauptman, MD a, Henry T. Robertson, PhD a, b, Eric Finzi, MD, PhD c, Tillman H.C. Kruger, MD d, M. Axel Wollmer, MD e, Michelle Magid, MD a
a University of Texas at Austin, Dell Medical School, Austin, Texas 
b Seton Family of Hospitals, Austin, Texas 
c Chevy Chase Cosmetic Center, Maryland 
d Center of Mental Health, Hannover Medical School, Germany 
e Asklepios Clinic North–Ochsenzoll, Hamburg, Germany 

Correspondence to: Jason S. Reichenberg, MD, Seton Family of Hospitals, 313 E 12 St, Suite 103, Austin, TX 78701

 Funding sources: None.
 Disclosure: Dr Magid received a research grant from the Brain and Behavior Institute, National Alliance for Research on Schizophrenia and Depression Young Investigator award, to fund one of the studies on which these data are based (grant number 17648). The grant went to Seton Family of Hospitals, which then provided salary support to Dr Magid for that research. After completion and as a result of the study, Dr Magid became a consultant with Allergan in November 2012 to discuss study findings. Dr Reichenberg's spouse (Dr Magid) became a consultant with Allergan in November 2012. Dr Kruger received honoraria for talks from Servier and Lundbeck. These activities were unrelated to the study. In April 2012, after completion and as a result of his initial study on botulinum toxin for depression, he became a member of an advisory board with Allergan. Dr Wollmer has received financial support for research through his institution, Asklepios Hamburg GmbH. He also received honoraria for talks from Merz, Novartis, Lundbeck, and Eli Lilly. These activities were unrelated to the study. In April 2012, after completion and as a result of his initial study on botulinum toxin for depression, he became a consultant and a member of an advisory board with Allergan. Dr Hauptman has received financial support for research through his institution for a study unrelated to this subject. Dr Finzi has received a patent to treat depression with BTA. Dr Robertson has no conflicts of interest to declare.
 Preliminary data from this paper were presented at the Texas Dermatological Society Meeting in Austin, Texas on May 1, 2015.
 The studies upon which the data used in this article are based was approved by the Seton Family of Hospitals institutional review board (IRB) (Dr Magid), the Quorum Review IRB (Dr Finzi), and the Ethics Committee of Basel (Dr Wolmer). Each trial was registered under clinicaltrials.gov under study numbers NCT01392963, NCT01556971, and NCT00934687, respectively.


Top of the page

© 2015  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline